Tin tức & Cập nhật

People with diabetes mellitus (DM) have a higher risk of pancreatic cancer than those without DM, reveals a recent study. Among diabetic individuals, those with new-onset DM show a greater pancreatic cancer risk than those with long-standing DM.

In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRAS^G12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRAS^G12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.

In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.

For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.

Patients who have been diagnosed with colorectal cancer (CRC) may benefit from increased flavonoid intake, which has been shown to reduce CRC-specific mortality in a recent study.

Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.